ADC Therapeutics SA (ADCT) Tops Q3 EPS by 23c

ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.41), $0.23 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $14.49 million versus the consensus estimate of $15.99 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c